Janus kinase inhibitors in autoimmune bullous diseases

D Huang, Y Zhang, L Kong, J Lu, Y Shi - Frontiers in Immunology, 2023 - frontiersin.org
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that
target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for …

A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders

Y Kalantari, S Sadeghi, D Asadi, A Goodarzi - International …, 2022 - Elsevier
Janus kinases (JAKs) are a group of intracytoplasmic tyrosine kinase proteins that bind to
the cytoplasmic part of the transmembrane cytokine receptors and regulate signaling. The …

Coexistence of Pemphigus Vulgaris and Lichen Planus following COVID‐19 vaccination

Z Aryanian, K Balighi, A Azizpour… - Case Reports in …, 2022 - Wiley Online Library
SARS‐CoV‐2 vaccines were approved without long‐term monitoring due to emergent
situation and might have several side effects. Herein, we describe the first case with …

SARS‐CoV‐2 vaccination and practical points in psoriasis patients: a narrative review

Z Aryanian, K Balighi, P Hatami, A Goodarzi… - Dermatologic …, 2022 - Wiley Online Library
SARS‐CoV2 vaccines were approved without long‐term monitoring due to emergent
situations. This has raised some issues about timing and protocol of receiving vaccines in …

New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case report

F Mohaghegh, P Hatami, A Refaghat… - Clinical Case …, 2022 - Wiley Online Library
Abstract Development of pemphigus foliaceus (PF) following SARS‐CoV‐2 infection has
only been reported in one patient who had received Bamlanivimab and thus might be …

Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence

GN Pathak, P Agarwal, SM Wolfe… - The Journal of …, 2024 - Wiley Online Library
Pemphigus represents a spectrum of potentially life‐threatening autoimmune‐mediated skin
blistering conditions caused by antibody production against desmoglein 1 and 3 (anti‐DSG …

Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients: new evidence for the safety of rituximab

Z Aryanian, A Tahooneban, K Balighi… - Dermatologic …, 2022 - Wiley Online Library
Although the treatments of pemphigus and pemphigoid patients have tended toward safer
options, patients with chronic infections seem to be still at the risk of infection reactivation …

COVID outcome in pemphigus: Does rituximab make pemphigus patients susceptible to more severe COVID‐19?

Z Aryanian, K Balighi, B Sajad… - Journal of Cosmetic …, 2023 - Wiley Online Library
Background The COVID‐19 pandemic has raised some concerns regarding the
management of chronic skin diseases, especially in patients on immunosuppressive therapy …

A Comparative Study of Demographic and Clinical Criteria Between Male and Female Patients With Pemphigus Referred to a Referral Hospital in Iran

Z Aryanian, K Balighi, N Esmaeli… - Dermatology …, 2024 - Wiley Online Library
Background: Pemphigus is a rare autoimmune disease characterized by the formation of
blisters on the skin and mucous membranes, caused by autoantibodies against desmoglein …

Kaposi's sarcoma in a patient with pemphigus vulgaris mimicking exacerbation of pemphigus

K Balighi, M Ghiasi, Z Aryanian, Z Nikyar… - Cancer …, 2023 - Wiley Online Library
Background Kaposi's sarcoma (KS) is a rare multifocal angiogenic tumor often seen in
immunocompromised setting such as acquired immunodeficiency syndrome (AIDS) or organ …